Literature DB >> 16465529

Mechanisms of neurodegeneration in neuronal ceroid-lipofuscinoses.

Yasuo Hachiya1, Masaharu Hayashi, Satoko Kumada, Akira Uchiyama, Kuniaki Tsuchiya, Kiyoko Kurata.   

Abstract

Neuronal ceroid-lipofuscinoses (NCL) are a group of neurodegenerative diseases and autosomal recessive lysosomal storage disorders. We examined the involvement of cell death, oxidative stress, and glutamate excitotoxicity using immunohistochemistry against Bcl-2, Bcl-x, oxidative products to proteins, lipids and DNA, calcium-binding proteins (calbindin-D28K, parvalbumin, calretinin), and glial glutamate transporters (excitatory amino acid transporters 1 and 2), in addition to terminal deoxynucleotidyl transferase-mediated dUTP-nick end labeling (TUNEL) in the brains from three cases of late infantile form of NCL (LINCL) and one case of juvenile form of NCL (JNCL) to investigate the neurodegenerative mechanisms. In the cerebral and cerebellar cortex, all of three LINCL cases demonstrated neurons with TUNEL-immunoreactive nuclei, whereas the JNCL case did not show TUNEL-immunoreactive nuclei. The coexistence of the nuclear TUNEL-immunoreactivity nuclei and cytoplasmic deposition of 4-hydroxy-2-nonenal-modified protein in the frontal cortex and hypoglossal nucleus may suggest a possible interrelationship between DNA fragmentation and lipid oxidation in LINCL. Additionally, glycoxidation of protein and oxidative stress to DNA seemed to be involved in the cerebellar and cerebral degeneration, respectively. Interneurons immunoreactive for calbindin-D28K and parvalbumin were severely reduced in the cerebral cortex, whereas those for calretinin were comparatively well preserved in LINCL, indicating the possibility of altered GABAergic system. The disturbance of expression of glial glutamate transporters seemed to be heterogeneous and mild. These findings suggest the possibility of new treatments for neurodegeneration in LINCL using antioxidative agents and/or GABAergic medications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16465529     DOI: 10.1007/s00401-005-0024-x

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  10 in total

Review 1.  Common and uncommon pathogenic cascades in lysosomal storage diseases.

Authors:  Einat B Vitner; Frances M Platt; Anthony H Futerman
Journal:  J Biol Chem       Date:  2010-04-29       Impact factor: 5.157

2.  Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis.

Authors:  Arunava Ghosh; Suresh Babu Rangasamy; Khushbu K Modi; Kalipada Pahan
Journal:  J Neurochem       Date:  2017-04-03       Impact factor: 5.372

3.  Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2,2)-dimethyl butyrate, a brain endogenous ligand of PPARα: Implications for late-infantile Batten disease therapy.

Authors:  Sudipta Chakrabarti; Sujyoti Chandra; Avik Roy; Sridevi Dasarathi; Madhuchhanda Kundu; Kalipada Pahan
Journal:  Neurobiol Dis       Date:  2019-03-28       Impact factor: 5.996

4.  Altered glutamate receptor function in the cerebellum of the Ppt1-/- mouse, a murine model of infantile neuronal ceroid lipofuscinosis.

Authors:  Rozzy Finn; Attila D Kovács; David A Pearce
Journal:  J Neurosci Res       Date:  2011-10-04       Impact factor: 4.164

5.  A Novel Porcine Model of CLN2 Batten Disease that Recapitulates Patient Phenotypes.

Authors:  Vicki J Swier; Katherine A White; Tyler B Johnson; Jessica C Sieren; Hans J Johnson; Kevin Knoernschild; Xiaojun Wang; Frank A Rohret; Christopher S Rogers; David A Pearce; Jon J Brudvig; Jill M Weimer
Journal:  Neurotherapeutics       Date:  2022-09-13       Impact factor: 6.088

6.  Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor α: implications for late infantile Batten disease therapy.

Authors:  Arunava Ghosh; Grant T Corbett; Frank J Gonzalez; Kalipada Pahan
Journal:  J Biol Chem       Date:  2012-09-18       Impact factor: 5.157

7.  Assessing disease severity in late infantile neuronal ceroid lipofuscinosis using quantitative MR diffusion-weighted imaging.

Authors:  J P Dyke; H U Voss; D Sondhi; N R Hackett; S Worgall; L A Heier; B E Kosofsky; A M Uluğ; D C Shungu; X Mao; R G Crystal; D Ballon
Journal:  AJNR Am J Neuroradiol       Date:  2007-08       Impact factor: 3.825

8.  Glial cells are functionally impaired in juvenile neuronal ceroid lipofuscinosis and detrimental to neurons.

Authors:  Lotta Parviainen; Sybille Dihanich; Greg W Anderson; Andrew M Wong; Helen R Brooks; Rosella Abeti; Payam Rezaie; Giovanna Lalli; Simon Pope; Simon J Heales; Hannah M Mitchison; Brenda P Williams; Jonathan D Cooper
Journal:  Acta Neuropathol Commun       Date:  2017-10-17       Impact factor: 7.801

Review 9.  Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview.

Authors:  Alessandro Simonati; Ruth E Williams
Journal:  Front Neurol       Date:  2022-03-11       Impact factor: 4.003

Review 10.  Neuroinflammatory paradigms in lysosomal storage diseases.

Authors:  Megan E Bosch; Tammy Kielian
Journal:  Front Neurosci       Date:  2015-10-30       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.